A new analysis from the peripheral arterial disease (PAD) subgroup of the large-scale COMPASS trial show that development of a major adverse limb event — the primary endpoint of the study — is ...
ORLANDO, FL—Using the combination of low-dose rivaroxaban (Xarelto; Bayer/Janssen) and aspirin in patients with stable lower-extremity PAD pays dividends not only in preventing major adverse limb ...
Presenting the results from the PAD subgroup at the European Society of Cardiology (ESC) 2017 Congress, Dr Sonia Anand (McMaster University, Hamilton, ON), said: "Until now we haven't had a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback